LT2964769T - Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį - Google Patents

Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį

Info

Publication number
LT2964769T
LT2964769T LTEP14759837.9T LT14759837T LT2964769T LT 2964769 T LT2964769 T LT 2964769T LT 14759837 T LT14759837 T LT 14759837T LT 2964769 T LT2964769 T LT 2964769T
Authority
LT
Lithuania
Prior art keywords
cell targeting
enabling control
cytomegalovirus vectors
vectors enabling
cytomegalovirus
Prior art date
Application number
LTEP14759837.9T
Other languages
English (en)
Inventor
Louis Picker
Scott Hansen
Klaus Frueh
Daniel MALOULI
Original Assignee
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University filed Critical Oregon Health & Science University
Publication of LT2964769T publication Critical patent/LT2964769T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP14759837.9T 2013-03-05 2014-03-05 Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį LT2964769T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772962P 2013-03-05 2013-03-05
PCT/US2014/020690 WO2014138209A1 (en) 2013-03-05 2014-03-05 Cytomegalovirus vectors enabling control of t cell targeting

Publications (1)

Publication Number Publication Date
LT2964769T true LT2964769T (lt) 2018-12-10

Family

ID=51491903

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14759837.9T LT2964769T (lt) 2013-03-05 2014-03-05 Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį

Country Status (13)

Country Link
US (3) US9783823B2 (lt)
EP (2) EP3473723A1 (lt)
JP (1) JP6483033B2 (lt)
AU (2) AU2014225886B2 (lt)
BR (1) BR112015021945A8 (lt)
CA (1) CA2904001C (lt)
DK (1) DK2964769T3 (lt)
ES (1) ES2696703T3 (lt)
HR (1) HRP20181930T1 (lt)
LT (1) LT2964769T (lt)
PL (1) PL2964769T3 (lt)
SI (1) SI2964769T1 (lt)
WO (1) WO2014138209A1 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351636B1 (en) 2010-05-14 2020-07-01 Oregon Health & Science University Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from a paramyxoviridae virus and uses thereof
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9783823B2 (en) 2013-03-05 2017-10-10 Oregon Health & Science University Cytomegalovirus vectors enabling control of T cell targeting
SG11201700315YA (en) 2014-07-16 2017-02-27 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3256595A4 (en) 2015-02-10 2018-09-26 Oregon Health & Science University Methods and compositions useful in generating non canonical cd8+ t cell responses
MA43285A (fr) 2015-11-20 2018-09-26 Univ Oregon Health & Science Vecteurs cmv comprenant des éléments de reconnaissance des microarn
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EP3475446A1 (en) * 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
CA3040303A1 (en) * 2016-10-18 2018-04-26 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
AU2020243095A1 (en) 2019-03-21 2021-10-21 21C Bio Vaccine to pathogenic immune activation cells during infections
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
US10632186B1 (en) 2019-03-21 2020-04-28 21C Bio Vaccine to pathogenic immune activation cells during infections
WO2021045969A1 (en) 2019-08-29 2021-03-11 Vir Biotechnology, Inc. Hepatitis b virus vaccines
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
EP4396208A1 (en) 2021-08-31 2024-07-10 VIR Biotechnology, Inc. Tuberculosis vaccines
IL310663A (en) 2021-08-31 2024-04-01 Vir Biotechnology Inc Recombinant HCMV vectors and their uses
WO2024121424A1 (en) 2022-12-09 2024-06-13 Daniel Zagury Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
DE3853139T2 (de) 1987-06-26 1995-06-14 Syntro Corp Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
EP1092775A1 (en) 1991-07-05 2001-04-18 American Cyanamid Company Methods for identifiying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus
JPH09512177A (ja) * 1994-04-29 1997-12-09 ファルマシア・アンド・アップジョン・カンパニー ネコ免疫不全ウイルスワクチン
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
AU711121B2 (en) 1995-02-21 1999-10-07 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
EP0966301B1 (en) 1996-07-31 2005-02-09 Ortho-McNeil Pharmaceutical, Inc. Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression
DE19733364A1 (de) 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
WO2002066629A2 (en) * 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
GB0122232D0 (en) 2001-09-14 2001-11-07 Medical Res Council Gene expression
EP1427826B1 (en) 2001-09-20 2011-04-20 Glaxo Group Limited HIV- RT-nef-Gag codon optimised DNA vaccines
US20030118568A1 (en) * 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
DE10232322A1 (de) * 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
WO2005012545A2 (en) 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
US20080044384A1 (en) 2004-06-25 2008-02-21 Medlmmune Vaccines, Inc. Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
US20100142823A1 (en) 2007-03-07 2010-06-10 Ze Wang 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction
JP2012519484A (ja) 2009-03-06 2012-08-30 マウント・シナイ・スクール・オヴ・メディシン マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン
SG181901A1 (en) * 2009-12-23 2012-08-30 4Antibody Ag Binding members for human cytomegalovirus
US20120289760A1 (en) * 2010-01-27 2012-11-15 Hill Ann B Cytomegalovirus-based immunogenic preparations
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
SG10201503450WA (en) * 2010-05-05 2015-06-29 Thirion Christian Vaccine against beta-herpesvirus infection and use thereof
EP3351636B1 (en) * 2010-05-14 2020-07-01 Oregon Health & Science University Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from a paramyxoviridae virus and uses thereof
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
US9783823B2 (en) 2013-03-05 2017-10-10 Oregon Health & Science University Cytomegalovirus vectors enabling control of T cell targeting
SG11201700315YA (en) 2014-07-16 2017-02-27 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
EP3256595A4 (en) 2015-02-10 2018-09-26 Oregon Health & Science University Methods and compositions useful in generating non canonical cd8+ t cell responses
MA43285A (fr) 2015-11-20 2018-09-26 Univ Oregon Health & Science Vecteurs cmv comprenant des éléments de reconnaissance des microarn
EP3475446A1 (en) * 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
CA3040303A1 (en) 2016-10-18 2018-04-26 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Also Published As

Publication number Publication date
US20200140888A1 (en) 2020-05-07
US20180087069A1 (en) 2018-03-29
US10316334B2 (en) 2019-06-11
JP2016513960A (ja) 2016-05-19
DK2964769T3 (en) 2018-12-10
US20160010112A1 (en) 2016-01-14
AU2014225886A1 (en) 2015-10-15
EP2964769A1 (en) 2016-01-13
CA2904001C (en) 2021-07-13
EP2964769A4 (en) 2016-08-31
AU2014225886B2 (en) 2020-04-16
JP6483033B2 (ja) 2019-03-13
CA2904001A1 (en) 2014-09-12
BR112015021945A8 (pt) 2019-12-03
SI2964769T1 (sl) 2018-12-31
PL2964769T3 (pl) 2019-03-29
EP2964769B1 (en) 2018-08-22
HRP20181930T1 (hr) 2019-01-11
ES2696703T3 (es) 2019-01-17
BR112015021945A2 (pt) 2017-07-18
US9783823B2 (en) 2017-10-10
AU2020204529A1 (en) 2020-07-30
WO2014138209A1 (en) 2014-09-12
EP3473723A1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
HRP20181930T1 (hr) Citomegalovirus vektori za kontroliranje ciljanja t-stanica
GB2512727B (en) Tracking control flow of instructions
IL244791A0 (en) Methods for modifying a host cell
GB2506589B (en) Launch control
EP2961625A4 (en) DAMPER WITH AUTONOMOUS CONTROL
EP2955114A4 (en) STABILIZATION SCHWUNGRAD
EP2950414A4 (en) ELECTRIC SYSTEM CONTROL SYSTEM
GB201306967D0 (en) Control of flow networks
EP2970988A4 (en) CONTROL OF PHASES OF GROWTH INDUCTION PRODUCTION
EP2972645A4 (en) CONTROL SYSTEM FOR POWER CONTROL
EP2798434A4 (en) CONTROL SYSTEM FOR VOLTAGE REGULATORS
AP2016009252A0 (en) Blasting system control
GB2520110B (en) State of charge indication
GB201308088D0 (en) Control
SG10201400576PA (en) Chamber matching using voltage control mode
EP3079219A4 (en) CHARGING CONTROL DEVICE
GB2517523B (en) Flywheel control scheme
EP2972668A4 (en) CONTROL SYSTEM FOR POWER CONTROL
GB2514302B (en) Control of line power
HK1223124A1 (zh) 用於轉基因表達的載體
GB201314611D0 (en) Power system control
GB201312800D0 (en) mGlu5 modulators
GB201308560D0 (en) Temperature control
PL2687809T3 (pl) Naprowadzanie pocisku
GB201810509D0 (en) Charging system